<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704104</url>
  </required_header>
  <id_info>
    <org_study_id>AC5-1</org_study_id>
    <nct_id>NCT02704104</nct_id>
  </id_info>
  <brief_title>Safety and Performance Evaluation of the Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions</brief_title>
  <official_title>A Randomized Controlled Single-Blind Investigation to Evaluate the Safety and Performance of the AC5 Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCH Therapuetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCH Therapuetics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to monitor patient safety after excision of skin lesions and
      subsequent application of AC5 topical hemostatic agent and to assess the performance of AC5
      for controlling bleeding in skin wounds.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of serious adverse events during the 30 days of follow-up</measure>
    <time_frame>30 Days Post Procedure</time_frame>
    <description>Local reactions to clinical investigation product (pain, edema, rash, cellulitis, localized infectious processes, other) detected during clinical investigation follow up.
Systemic reactions after administration of clinical investigation product (fever, allergic reaction, anaphylaxis or any clinical untoward event) detected during clinical investigation follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to hemostasis in seconds per square centimetre wound area</measure>
    <time_frame>At time of application (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to hemostasis (seconds)</measure>
    <time_frame>At time of application (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASEPSIS wound scores at Day 7 and Day 30</measure>
    <time_frame>7 and 30 Days Post Procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Skin Neoplasms</condition>
  <arm_group>
    <arm_group_label>AC5 Treatment on Wound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of skin lesion with topical hemostatic (AC5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment of Wound</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of skin lesion with water resistant dressing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Application of AC5 Hemostatic agent</intervention_name>
    <description>Application of the hemostatic agent will be applied to the skin lesion directly as prescribed</description>
    <arm_group_label>AC5 Treatment on Wound</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard application of water resistant dressing</intervention_name>
    <description>Application of a water resistant dressing to the skin lesion as prescribed</description>
    <arm_group_label>Standard Treatment of Wound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between the ages of 18 and 85.

          -  Voluntary written informed consent, given before performance of any clinical
             investigation-related procedure not part of standard medical care, and with the
             understanding that consent may be withdrawn at any time without prejudice to future
             medical care.

          -  Scheduled for excision of 2 (two) or more skin lesions from their trunk or upper limbs
             (defined as lying below the level of the inferior border of the patient's mandible).

          -  If subjects is currently prescribed an antiplatelet therapy, it must from one of the
             following therapies at levels as per hospital protocol:

          -  Antiplatelet monotherapy with one of the following agents:

               -  Aspirin

               -  Clopidogrel (thienopyridine-class antiplatelet agent)

               -  Ticagrelor

               -  Dipyridamole

          -  Female subjects must meet at least one of the following additional criteria:

               -  Surgically sterile with bilateral tubal ligation or hysterectomy.

               -  Post-menopausal for at least one year.

               -  If of child-bearing potential, practicing an acceptable method of birth control
                  for the duration of the clinical investigation as judged by the Investigator,
                  such as condoms, foams, jellies, diaphragm, intrauterine device or abstinence.

          -  Subjects willing to undergo pre-and post-clinical investigation blood and urine
             collection, physical exams and laboratory investigations.

        Exclusion Criteria:

          -  Active infection as demonstrated by temperature &gt; 37.5 C and clinical features of
             active infection.

          -  Wound expected to expose bone or tendon.

          -  Wound expected to require topical antibiotics.

          -  Know contraindication or reaction to Tegaderm use.

          -  Presence of malignancy or clinical expectation of malignancy based on examination.

          -  Known immunosuppression or taking immunosuppressive agents including systemic
             steroids.

          -  Plan for adjunctive flap or graft procedure to obtain closure of the wound(s) subject
             to this study.

          -  History of severe co-morbidity with expected patient survival ≤ 6 months.

          -  Pregnancy or lactation

          -  Intake of investigational drugs within 28 days prior to enrollment.

          -  Currently taking oral anticoagulants

          -  History of concurrent condition that, in the Investigator's opinion, would jeopardize
             the safety of the subject or compliance with the protocol.

          -  History of clinically significant, active disease (within 12 months prior to
             enrollment) of the pulmonary, gastrointestinal, neurological, genitourinary, renal, or
             haematological system, that in the opinion of the Principal Investigator, may confound
             the results of the trial or pose additional risk to the subject following the
             administration of AC5.

          -  History of clinically significant cardiac disorder, defined as: acute coronary
             syndrome, congestive heart failure (NYHA class III/IV), diagnosis of unstable angina
             pectoris, cerebral stroke and or myocardial infarction within the last 12 months or
             planned coronary or carotid revascularisation procedures anytime through 30 Day
             follow-up.

          -  History of severe uncontrolled treated or untreated hypertension (systolic blood
             pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg).

          -  Likely inability to comply with the protocol or cooperate fully with the investigator
             and site personnel.

          -  Presence of significant cognitive impairment (Mini Mental Status Examination &lt;22) or
             mental incapacity.

          -  Unwillingness or language barrier precluding adequate understanding of the trial
             procedure or cooperation with trial site personnel.

          -  Known or suspected active abuse of alcohol, narcotics or non-prescription drugs.

          -  Other planned surgical procedures within 30 days prior to or 30 days post-index
             procedure.

          -  Prior enrollment in this AC5 clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack Kelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Colllege Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>June 20, 2017</submitted>
    <returned>November 3, 2017</returned>
    <submitted>November 6, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

